Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Ryvu Therapeutics logo — Developing novel treatments at the forefront of oncology

Ryvu Therapeutics

Developing novel treatments at the forefront of oncology

Founded 2007 Poland Poland 284 employees Post-IPO Debt Biotechnology, Health Care +1

General Information

Company Name Ryvu Therapeutics
Founded Year 2007
Location Poland Poland
Employees 284
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Debt
Social

BounceWatch is an independent company data service, not affiliated with Ryvu Therapeutics. To contact Ryvu Therapeutics, visit ryvu.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ryvu Therapeutics compare?

A PDF of Ryvu Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ryvu Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ryvu Therapeutics

Ryvu Therapeutics is a clinical-stage drug discovery and development company focused on novel small molecule therapies that address emerging targets in oncology. Internally discovered pipeline candidates make use of diverse therapeutic mechanisms driven by emerging knowledge of cancer biology, including small molecules directed at kinase, synthetic lethality, and immuno-oncology targets. Ryvu’s most advanced programs are RVU120 - a selective CDK8/CDK19 kinase inhibitor with potential for the treatment of hematological malignancies and solid tumors currently in Phase I clinical development for the treatment of acute myeloid leukemia and myelodysplastic syndrome, and Phase I/II for the treatment of r/r metastatic or advanced solid tumors, and SEL24 (MEN1703) - dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, currently in Phase II clinical studies in acute myeloid leukemia. In its history, Ryvu Therapeutics has signed 11 partnering and licensing deals with global companies, among others Merck, Menarini Group, Galapagos, Exelixis, and BioNTech. The company was founded in 2007 and is headquartered in Krakow, Poland. Ryvu is listed on the Warsaw Stock Exchange and is a component of sWIG80 index.

No funding data available for Ryvu Therapeutics yet.

Ryvu Therapeutics Alternatives & Competitors

View All Alternatives
Ryvu Therapeutics vs
Biosight Ltd.
Biosight Ltd. Israel

Developing innovative pharmaceuticals for hematological malignancies and disorders

Series C
3 employees
Biotechnology, Health Care
Ryvu Therapeutics vs
Curis
Curis United States

Working relentlessly to develop innovative and differentiated therapeutics that improve the lives of...

Post-IPO Equity
133 employees
Biotechnology, Health Care
Compare Ryvu Therapeutics vs Curis
Ryvu Therapeutics vs
Polymed Biopharmaceuticals
Polymed Biopharmaceuticals China

Polymed creates novel PROTAC therapies for cancers and immunology HPB-143 (IRAK4) & HPB-092 (FLT3/...

Series A
2 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Ryvu Therapeutics

Developing novel treatments at the forefront of oncology
Ryvu Therapeutics was founded in 2007.
Ryvu Therapeutics is headquartered in Poland.
Ryvu Therapeutics operates in Biotechnology, Health Care and Pharmaceutical.
Ryvu Therapeutics has approximately 284 employees.
Top alternatives and competitors to Ryvu Therapeutics include Biosight Ltd., Curis, Polymed Biopharmaceuticals, Actinium Pharmaceuticals, Inc., Tarveda Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ryvu Therapeutics and Biosight Ltd. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ryvu Therapeutics, https://bouncewatch.com/company/ryvu-therapeutics, updated 6 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout